C2i Genomics and Karkinos Healthcare Partner to Bring AI-Powered Cancer Detection and Monitoring to India, C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Mumbai, 03 June 2022 (GNI): C2i Genomics, a cancer intelligence company, today announced a strategic partnership with Karkinos Healthcare, a technology led managed care platform for cancer, to co-develop the minimal residual disease (MRD) market…






